Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
AMLX

AMLX - Amylyx Pharmaceuticals, Inc. Stock Price, Fair Value and News

1.71USD-0.03 (-1.72%)Market Closed

Market Summary

AMLX
USD1.71-0.03
Market Closed
-1.72%

AMLX Stock Price

View Fullscreen

AMLX RSI Chart

AMLX Valuation

Market Cap

116.3M

Price/Earnings (Trailing)

-1.64

Price/Sales (Trailing)

0.29

EV/EBITDA

0.84

Price/Free Cashflow

7.53

AMLX Price/Sales (Trailing)

AMLX Profitability

EBT Margin

-16.50%

Return on Equity

-21.91%

Return on Assets

-17.03%

Free Cashflow Yield

13.28%

AMLX Fundamentals

AMLX Revenue

Revenue (TTM)

398.0M

Rev. Growth (Yr)

24.1%

Rev. Growth (Qtr)

-18.26%

AMLX Earnings

Earnings (TTM)

-71.1M

Earnings Growth (Yr)

-7.7K%

Earnings Growth (Qtr)

-2.6K%

Breaking Down AMLX Revenue

Last 7 days

-2.8%

Last 30 days

-6.0%

Last 90 days

-46.1%

Trailing 12 Months

-93.2%

How does AMLX drawdown profile look like?

AMLX Financial Health

Current Ratio

4.48

AMLX Investor Care

Shares Dilution (1Y)

1.24%

Diluted EPS (TTM)

-1.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024398.0M000
2023111.9M201.5M291.1M380.8M
20220011.3M22.2M
2021000285.0K

Tracking the Latest Insider Buys and Sells of Amylyx Pharmaceuticals, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 15, 2024
mazzariello gina
sold
-39,308
1.8799
-20,910
chief legal officer
May 15, 2024
quimi daphne
bought
4,252
1.8899
2,250
-
May 14, 2024
quimi daphne
bought
5,183
1.885
2,750
-
Apr 16, 2024
mazzariello gina
acquired
-
-
80,560
chief legal officer
Apr 16, 2024
cohen joshua b
acquired
-
-
179,850
co-chief executive officer
Apr 16, 2024
klee justin b.
acquired
-
-
179,850
co-chief executive officer
Apr 16, 2024
bedrosian camille l
acquired
-
-
96,910
chief medical officer

1–10 of 50

Which funds bought or sold AMLX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
new
-
823,181
823,181
0.06%
Jun 11, 2024
EverSource Wealth Advisors, LLC
new
-
9,940
9,940
-%
Jun 04, 2024
DekaBank Deutsche Girozentrale
sold off
-100
-1,224,000
-
-%
May 29, 2024
INSTRUMENTAL WEALTH, LLC
new
-
3,055,960
3,055,960
1.33%
May 29, 2024
Pathway Financial Advisers, LLC
new
-
4,754
4,754
-%
May 24, 2024
Cetera Investment Advisers
added
100
656,283
1,264,000
-%
May 24, 2024
Cetera Investment Advisers
added
97.37
3,163,210
5,407,590
0.01%
May 24, 2024
Cetera Investment Advisers
new
-
387,692
387,692
-%
May 24, 2024
Cetera Investment Advisers
new
-
1,739,800
1,739,800
-%
May 24, 2024
Cetera Investment Advisers
new
-
3,905,320
3,905,320
0.01%

1–10 of 46

Are Funds Buying or Selling AMLX?

Are funds buying AMLX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AMLX
No. of Funds

Unveiling Amylyx Pharmaceuticals, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 11, 2024
panacea innovation ltd
6.2%
4,200,000
SC 13G
Feb 14, 2024
point72 asset management, l.p.
4.1%
2,751,305
SC 13G/A
Feb 14, 2024
perceptive advisors llc
2.8%
1,869,125
SC 13G/A
Feb 14, 2024
viking global investors lp
4.4%
2,962,555
SC 13G/A
Feb 13, 2024
vanguard group inc
7.81%
5,275,566
SC 13G/A
Jan 29, 2024
blackrock inc.
5.9%
4,002,334
SC 13G
Dec 11, 2023
point72 asset management, l.p.
4.7%
3,176,105
SC 13G
Oct 04, 2023
morningside venture investments ltd
3.43%
2,313,227
SC 13D/A
Aug 17, 2023
morningside venture investments ltd
6.86%
4,618,846
SC 13D/A
Jun 09, 2023
goldman sachs group inc
5.4%
3,653,782
SC 13G

Recent SEC filings of Amylyx Pharmaceuticals, Inc.

View All Filings
Date Filed Form Type Document
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 06, 2024
8-K
Current Report
May 16, 2024
4
Insider Trading
May 16, 2024
4
Insider Trading
May 15, 2024
144
Notice of Insider Sale Intent
May 09, 2024
10-Q
Quarterly Report

Peers (Alternatives to Amylyx Pharmaceuticals, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
56.6B
6.8B
17.55% 15.42%
-9.49
8.27
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.1B
2.0B
6.10% -19.49%
-60.58
10.04
75.20% 68.82%
16.1B
2.5B
5.03% -10.77%
78.14
6.5
13.74% 186.89%
13.5B
3.8B
4.06% -3.24%
18.05
3.57
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.63% 71.22%
-9.82
48.09
54.84% -28.31%
5.2B
524.1M
-1.19% -54.45%
-12.36
9.84
394.93% 39.61%
3.4B
251.0M
-5.41% -4.45%
-11.47
13.54
73.58% -86.73%
3.2B
240.7M
16.82% -26.89%
-6.77
12.77
-1.03% -213.92%
2.5B
813.8M
1.25% -38.59%
-1.5K
3.12
56.43% 98.83%
2.2B
996.6M
20.98% 97.26%
-5.59
2.23
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-4.75% 32.39%
28.02
4.44
60.38% -34.49%
547.7M
881.7K
19.55% 492.49%
-16.22
481.06
-77.61% 33.36%
245.6M
4.2M
-16.55% 51.92%
-1.97
59.05
-66.30% 48.24%
22.0M
2.1M
40.11% 239.32%
-0.95
7.61
-13.45% 69.54%

Amylyx Pharmaceuticals, Inc. News

Latest updates
MarketBeat39 hours ago

Amylyx Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32021Q42021Q3
Revenue-18.3%88,643,000108,449,000102,693,00098,216,00071,428,00053,642,25035,856,50018,070,750285,000
Costs and Expenses97.9%210,773,000106,515,00083,973,00078,015,00073,481,00066,478,00055,026,000-23,203,000
  S&GA Expenses10.6%57,759,00052,241,00048,718,00043,391,00044,006,00040,844,00029,940,00014,921,00010,350,000
  R&D Expenses-18.5%36,608,00044,914,00030,037,00029,044,00024,192,00022,813,00024,914,00013,394,00012,853,000
EBITDA Margin-211.3%-0.160.150.02-0.35-1.32-8.87-16.30-308-
Income Taxes-86.2%242,0001,754,0001,500,0001,933,000-170,000579,000-125,000--
Earnings Before Taxes-1930.6%-118,551,0006,476,00022,411,00024,007,0001,403,000-42,125,000-53,881,000-28,344,000-23,142,000
EBT Margin-215.7%-0.160.140.02-0.35-1.33-8.89-16.33-308-
Net Income-2610.9%-118,793,0004,731,00020,893,00022,074,0001,573,000-42,704,000-53,756,000-28,344,000-23,142,000
Net Income Margin-238.1%-0.180.130.01-0.36-1.33-8.92-16.35-308-
Free Cashflow-104.2%-556,00013,195,000-5,526,0008,331,000-5,322,000-50,317,000-43,537,000-28,430,000-21,018,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q4
Assets-19.3%417517467454408391181225274106
  Current Assets-11.6%411465434427389382172216265105
    Cash Equivalents0.2%17117013524811563.0010867.0011050.00
  Inventory-100.0%-38.0032.0025.0013.0010.001.00---
  Net PPE-8.5%2.003.003.003.003.003.002.002.001.000.00
Liabilities10.7%93.0084.0048.0067.0055.0051.0037.0032.0033.0017.00
  Current Liabilities11.7%92.0082.0046.0064.0052.0047.0033.0027.0028.0017.00
Shareholder's Equity-25.1%324433418386353341144193241-
  Retained Earnings-39.0%-423-304-309-330-352-354-311-257-203-155
  Additional Paid-In Capital1.4%7487387287177056954564514455.00
Shares Outstanding0.4%68.0068.0068.0067.0067.0067.0056.0055.0052.007.00
Float----1,310---788--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q1
Cashflow From Operations-103.6%-48913,551-5,1698,609-5,072-49,697-43,078-46,462-40,634-28,244-20,865-13,047-12,643
  Share Based Compensation4.1%9,9249,53410,1769,9507,5016,0915,5245,7074,3921,091802657586
Cashflow From Investing-96.1%81920,925-108,088123,22255,994-228,18084,0414,462-99,3112,814-49,206--14.00
Cashflow From Financing-43.0%1312308891,3841,040232,162--828200,455-1,065131,6511,99325,927
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

AMLX Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Product revenue, net$ 88,643$ 71,428
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]us-gaap:ProductMemberus-gaap:ProductMember
Operating expenses:  
Cost of sales$ 5,945$ 5,283
Cost of sales - inventory impairment and loss on firm purchase commitments110,461 
Research and development36,60824,192
Selling, general and administrative57,75944,006
Total operating expenses210,77373,481
Loss from operations(122,130)(2,053)
Other income, net:  
Interest income4,3263,718
Other expense, net(747)(262)
Total other income, net3,5793,456
(Loss) income before income taxes(118,551)1,403
Provision (benefit) for income taxes242(170)
Net (loss) income$ (118,793)$ 1,573
Net (loss) income per share - basic$ (1.75)$ 0.02
Net (loss) income per share - diluted$ (1.75)$ 0.02
Weighted-average shares used in computing net (loss) income per share-basic67,854,35666,717,271
Weighted-average shares used in computing net (loss) income per share-diluted67,854,35670,863,665

AMLX Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 170,552$ 170,201
Short-term investments202,741201,161
Accounts receivable, net20,35140,050
Inventories 38,323
Prepaid expenses and other current assets16,89014,931
Total current assets410,534464,666
Property and equipment, net2,4592,686
Restricted cash equivalents719719
Operating lease right-of-use assets3,2523,725
Long-term inventories 44,957
Other assets493701
Total assets417,457517,454
Current liabilities:  
Accounts payable21,45322,061
Accrued expenses67,87457,724
Operating lease liabilities, current portion2,3122,257
Total current liabilities91,63982,042
Operating lease liabilities, net of current portion1,3821,980
Total liabilities93,02184,022
Commitments and contingencies (Note 11)
Stockholders' equity:  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized
Common stock, $0.0001 par value; 300,000,000 shares authorized; 67,975,587 and 67,707,432 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively77
Additional paid-in capital748,248738,177
Accumulated deficit(423,742)(304,949)
Accumulated other comprehensive (loss) income(77)197
Total stockholders' equity324,436433,432
Total liabilities and stockholders' equity$ 417,457$ 517,454
AMLX
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEhttps://amylyx.com
 INDUSTRYBiotechnology
 EMPLOYEES338

Amylyx Pharmaceuticals, Inc. Frequently Asked Questions


What is the ticker symbol for Amylyx Pharmaceuticals, Inc.? What does AMLX stand for in stocks?

AMLX is the stock ticker symbol of Amylyx Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amylyx Pharmaceuticals, Inc. (AMLX)?

As of Wed Jun 12 2024, market cap of Amylyx Pharmaceuticals, Inc. is 116.29 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMLX stock?

You can check AMLX's fair value in chart for subscribers.

What is the fair value of AMLX stock?

You can check AMLX's fair value in chart for subscribers. The fair value of Amylyx Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Amylyx Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AMLX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Amylyx Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether AMLX is over valued or under valued. Whether Amylyx Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Amylyx Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMLX.

What is Amylyx Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jun 12 2024, AMLX's PE ratio (Price to Earnings) is -1.64 and Price to Sales (PS) ratio is 0.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMLX PE ratio will change depending on the future growth rate expectations of investors.